source
- Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHDEpicrispr Biotechnologies announced a $90 million Series C financing to accelerate development of its epigenetic editing therapy EPI-321 for facioscapulohumeral muscular dystrophy (FSHD), a rare ge…
- Researchers suspect Exelixis used a minor tweak to cabozantinib to sidestep patent cliffExelixis' 2025 financial results highlighted the importance of its drug cabozantinib, which has been a major revenue source for the company. A group of analysts argue that the company introduced a…